key: cord-0016202-4rvi88qu
authors: Mathew, Bijo; Oh, Jong Min; Baty, Roua S.; Batiha, Gaber El-Saber; Parambi, Della Grace Thomas; Gambacorta, Nicola; Nicolotti, Orazio; Kim, Hoon
title: Piperazine-substituted chalcones: a new class of MAO-B, AChE, and BACE-1 inhibitors for the treatment of neurological disorders
date: 2021-03-20
journal: Environ Sci Pollut Res Int
DOI: 10.1007/s11356-021-13320-y
sha: 297d60faf4d9bc887ef14dc084c0fea568d39aec
doc_id: 16202
cord_uid: 4rvi88qu

Eleven piperazine-containing 1,3-diphenylprop-2-en-1-one derivatives (PC1-PC11) were evaluated for their inhibitory activities against monoamine oxidases (MAOs), cholinesterases (ChEs), and β-site amyloid precursor protein cleaving enzyme 1 (BACE-1) with a view toward developing new treatments for neurological disorders. Compounds PC10 and PC11 remarkably inhibited MAO-B with IC(50) values of 0.65 and 0.71 μM, respectively. Ten of the eleven compounds weakly inhibited AChE and BChE with > 50% of residual activities at 10 μM, although PC4 inhibited AChE by 56.6% (IC(50) = 8.77 μM). Compound PC3 effectively inhibited BACE-1 (IC(50) = 6.72 μM), and PC10 and PC11 moderately inhibited BACE-1 (IC(50) =14.9 and 15.3 μM, respectively). Reversibility and kinetic studies showed that PC10 and PC11 were reversible and competitive inhibitors of MAO-B with K(i) values of 0.63 ± 0.13 and 0.53 ± 0.068 μM, respectively. ADME predictions for lead compounds revealed that PC10 and PC11 have central nervous system (CNS) drug-likeness. Molecular docking simulations showed that fluorine atom and trifluoromethyl group on PC10 and PC11, respectively, interacted with the substrate cavity of the MAO-B active site. Our results suggested that PC10 and PC11 can be considered potential candidates for the treatment of neurological disorders such as Alzheimer’s disease and Parkinson’s disease.

Of the heterogeneous and complex neurodegenerative disorders (NDDs) that largely affect the elderly, Alzheimer's disease (AD) and Parkinson's disease (PD) are the most prevalent and their pathogenesis have been attributed to a variety of genomic, epigenomic, and environmental factors (Van Bulck et al. 2019) . Mounting evidence indicates that drugs targeting a single pathway cannot adequately address the multifactorial pathophysiologies of NDDs (Geldenhuys et al. 2011) . Oxidative stress, mitochondrial dysfunction, and imbalances in the levels of enzymes that control the metabolism of biogenic amines may promote NDD progression (Barnham et al. 2004; Lin and Beal 2006) . On the other hand, several molecular scaffolds have been designed to simultaneously target entities such as choline esterase (ChE), monoamine oxidases (MAOs), and β-site amyloid precursor protein cleaving enzyme 1 (β-secretase, BACE-1), to retard NDD progression .

Piperazine is a heteromonocyclic, six-membered ring containing two secondary nitrogen atoms, and diazacycloalkane with a non-planar, flexible nature that can interact hydrophobically and by hydrogen bonding with target enzymes. Furthermore, piperazine is a privileged structure with acknowledged "drug-likeness" and balanced pharmacodynamic and pharmacokinetic properties (Rathi et al. 2016) . Currently, more than 40 piperazine-containing drugs have been FDA-approved as antianginals, antidepressants, antiserotonergics, urologicals, anthelmintics, antineoplastic agents, nootropics, and tranquillizers (Brito et al. 2019) . Furthermore, the substitution of one or both nitrogen atoms in the piperazine ring system with various structural motifs can result in significant MAO-A, MAO-B, and acetylcholinesterase (AChE) inhibitions (Pettersson et al. 2012; Kaya et al. 2017; Kumar et al. 2018; Özdemir et al. 2020; Sağlık et al. 2020; Jevtić et al. 2020; Modh et al. 2013; Sahin et al. 2018) .

On the other hand, 1,3-diphenylprop-2-en-1-one is a chalcone that contains two phenyl rings separated by rotatable three-carbon units. This linker is an α, β-unsaturated ketone with trans-orientated olefinic linkage (Zhuang et al. 2017 ). More than 90% of the chalcones synthesized exhibit selective MAO-B inhibition (Chimenti et al. 2009; Guglielmi et al. 2020) , and analogs of chalcones with furan, thiophene, indole, imidazole, or morpholine heterocyclic entities on the A ring of α, β-unsaturated ketones have been reported to act as competitive, selective, and reversible MAO-B inhibitors (Robinson et al. 2013; Mathew et al. 2016; Sasidharan et al. 2016 Sasidharan et al. , 2018 Mathew et al. 2019a ). However, the effect of introducing the piperazine pharmacophore into the chalcone framework has not been explored in the context of MAO-B inhibition. Previously, new chalcones containing the piperazine or 2,5-dichlorothiophene moiety were synthesized and evaluated for antimicrobial activities (Tomar et al. 2007 ). Herein, we describe the synthesis of a series of piperazinederived chalcones and inspected for their abilities to inhibit MAOs, ChEs, and BACE-1 in an effort to identify novel treatments for NDDs.

Derivatives were synthesized using base-catalyzed Claisen-Schmidt condensation reaction between various aromatic aldehydes and 4′-piperazinoacetophenone (Tomar et al. 2007 ). Briefly, the synthesis was initiated by adding 0.01 M 4′-piperazinoacetophenone to an ethanol (20 ml)/40% of KOH (8 ml) mix and then adding 0.01 M of an aromatic benzaldehyde and stirring for 10-12 h (Scheme 1). Resulting solutions were poured into ice-cold water, and the precipitates were washed with water. The formation of the products was checked by thin layer chromatography with a solvent system of ethyl acetate: hexane (1:9). Recrystallization was done with ethanol.

Kynuramine (0.06 mM) and benzylamine (0.3 mM) were used as substrates to assay the activities of recombinant human MAO-A and MAO-B, respectively ]. AChE and butyrylcholinesterase (BChE) activities were assayed using Electrophorus electricus Type VI-S and Equine serum Type, respectively, in the presence of 0. [Ellman et al. 1961; Baek et al. 2018a; Lee et al. 2019 ]. Enzymes and inhibitors were preincubated for 15 min before measuring inhibitory activities. BACE-1 activity was determined using a βsecretase (BACE-1) activity detection kit, which included the 7-methoxycoumarin-4-acetyl-[Asn670,Leu671]-amyloid β/A4 protein fragment 667-676-(2,4-dinitrophenyl)Lys-Arg-Arg amide trifluoroacetate as a substrate. The reaction was performed for 2 h at 37°C and the signals were measured using a fluorescence spectrometer (FS-2, Scinco, Seoul, Korea) with an excitation wavelength of 320 nm and an emission wavelength of 405 nm. Chemicals, enzymes, and BACE-1 activity detection kits were purchased from Sigma-Aldrich (St. Louis, MO, USA).

The inhibitory activities of the 11 compounds were initially measured at a concentration of 10 μM against MAO-A, MAO-B, AChE, BChE, or BACE-1. IC 50 values for MAO-A and MAO-B by the compounds were determined first, and then, those for AChE, BChE, and BACE-1 by compounds with residual activities of < 50% were investigated. Kinetic studies were carried out on PC10 and PC11, which most potently inhibited MAO-B, at five substrate concentrations and three inhibitor concentrations, as previously described [Çeçen et al. 2020 ].

The reversibility of MAO-B inhibitions by PC10 and PC11 was assessed by dialysis after preincubating them at 0.15 μM with MAO-B for 30 min, as described previously [Baek et al. 2018b ]. For comparison purposes, MAO-B was preincubated with lazabemide (a reference reversible MAO-B inhibitor) or pargyline (a reference irreversible MAO-B inhibitor) at 0.20 and 0.30 μM, respectively. Reversibility patterns were assessed by comparing the activities of dialyzed (A D ) and undialyzed (A U ) samples. ADME parameters including pharmacokinetic data and physical-chemical properties such as lipophilicity and water solubility of PC10 and PC11 were predicted in silico using free software available at http://www.swissadme.ch/ (Daina et al. 2017 ).

The 3D-coordinates of MAO-A, MAO-B, and AChE crystals were collected from the Protein Data Bank by selecting 2Z5X, 2V5Z, and 4EY7 entries, respectively (Son 2008; Binda et al. 2007; Cheung et al. 2012) . Protein Preparation Wizard tools were employed to optimize and minimize crystal structures (Schrödinger 2020c; Madhavi Sastry et al. 2013) . To explore the chirality, ionization states, ring conformations, and tautomers of each input structure, PC4, PC10, and PC11 were treated by using the Ligprep tool (Schrödinger 2020b). Docking simulations were carried out using GLIDE (Friesner et al. 2004; Schrödinger 2020a) , and the centers of mass of cognate ligands were used to generate the enclosing boxes. The standard precision docking protocol was used with default Force Field OPLS_2005 and detailed analysis of ligand binding affinities was performed by calculating binding free energies (ΔG) between protein and ligands using the Molecular Mechanics/Generalized Born Surface Area (MM-GBSA) method (Banks et al. 2005; Genheden and Ryde 2015). The ΔG values were calculated using: ΔG bind = ΔE MM + ΔG solv + ΔG SA , where ΔE MM = minimized energy of the ligand-protein complex, ΔG solv = solvation energy, and ΔG SA = surface area energy.

All eleven compounds exhibited high inhibitory activities against MAO-B with residual activities of <50% at the concentration of 10 μM (Table 1) . PC10 exhibited the greatest inhibitory activity against MAO-B (IC 50 value = 0.65 μM), followed by PC11, which had an IC 50 value of 0.71 μM. PC1 inhibited MAO-B least (IC 50 = 7.62 μM), and the other 8 compounds had IC 50 values ranging from 1.09 to 3.65 μM. A comparison of the IC 50 value of PC1 with those of PC10 and PC11 indicated that the presence of a -F or -CF 3 group instead of -H increased MAO-B inhibitory activity. Other substituents such as -OCH 3 of PC3, -Cl of PC8, and -OH of PC2 moderately enhanced MAO-B inhibition. However, all compounds much less effectively inhibited MAO-A at 10 μM and achieved residual activities of > 65% (Table 1) Values for reference compounds were determined after preincubating them for 30 min with enzymes Interestingly, some of the compounds effectively inhibited BACE-1 (Table 1) . PC3 effectively inhibited BACE-1, and PC10 and PC11 showed moderate BACE-1 inhibitory activities with IC 50 values of 14.9 and 15.3 μM, respectively; these two compounds contained fluoro and trifluoromethyl pharmacophores, respectively, on a piperazine-substituted chalcone framework.

MAO-B inhibitions by PC10 and PC11 were subjected to kinetic analysis. Lineweaver-Burk and secondary plots showed that PC10 and PC11 competitively inhibited MAO-B (Fig. 1a and c) , with K i values of 0.63 ± 0.13 and 0.53 ± 0.068 μM, respectively ( Fig. 1b and d) . These experimental observations showed that PC10 and PC11 are competitive and selective inhibitors of MAO-B.

MAO-B inhibitions by PC10 and PC11 were also subjected to reversibility studies. The results obtained showed that inhibition of MAO-B by PC10 was recovered after dialysis from 32.1 (A U value) to 81.2% (A D value), and that inhibition by PC11 recovered from 32.6 (A U ) to 68.9% (A D ). These values were close to those of the reversible reference lazabemide (from 28.3 to 86.9%). On the other hand, inhibition of MAO-B by the irreversible reference pargyline was not recovered by dialysis (from 31.8 to 32.7%) (Fig. 2) . The above data revealed that MAO-B inhibitions by PC10 and 

In silico ADME prediction revealed that PC10 and PC11 fully complied with the limits of Lipinski's rule and supported their oral use and drug-likenesses (Table 2 ). In addition, the boiled-egg and bioavailability radar plots generated by the SwissADME tool also provided two clear ADME characteristics (Fig. 3) . Boiled-egg pictures represent passive absorption in the gastrointestinal (GI) tract (shown as the white area) and the ability to cross the blood-brain barrier (BBB; yellow area). These plots showed that PC10 and PC11 were located in the yellow area, suggesting ability to cross the BBB, and indicated that both would be passively absorbed in the GI system ( Fig. 3a and b) . Bioavailability radar also placed the drug-likeness representation of PC11 within the pink area, which is an indicator of optimal physicochemical properties, such as size, polarity, solubility, lipophilicity, saturation, and suitability for oral administration. In this respect, PC10 showed a slight deviation in physicochemical property of saturation ( Fig. 3c and d) .

Molecular docking simulations and binding free energies calculations were carried out to investigate molecular interactions between PC4, PC10, or PC11 and the binding sites of MAOs and AChE. PC10 and PC11 had docking scores of −5.73 and −4.81 kcal/mol, respectively, toward MAO-A, and of −7.29 and −7.11 kcal/mol, respectively, toward MAO-B (Table 3 ). In addition, the MM-GBSA values of PC10 and PC11 were −28.77 and −52.60 kcal/mol, respectively, toward MAO-A, and −64.19 and 66.06 kcal/mol, respectively, toward MAO-B (Table 3) . Regarding AChE inhibition, although docking simulation returned comparable scores for the three compounds, PC4 had the lowest binding free energy (i.e., −55.81, −39.82, and −52.18 kcal/mol for PC4, PC10, and PC11, respectively) ( Table 3) . The para-methyl and para-fluorine rings of PC4 and PC10 faced FAD and interacted through π-π contacts with Y407 of MAO-A (Fig. 4a) . Conversely, although slightly larger, the −CF 3 substituent of PC11 did not allow its styrene moiety to face FAD, which resulted in the phenyl ring of chalcone establishing π-π interactions with F208 of MAO-A. All three compounds assumed similar binding poses within the MAO-B binding pocket (Fig. 4b) , which was ascribed to the existence of two π-π interactions between chalcone aromatic rings and Y398 or Y326 of MAO-B selective residues. The styrene portion of PC4 established a π-π interaction with Y341 of AChE and the carbonyl group of its chalcone moiety formed a hydrogen bond with F295 of AChE (Fig. 4c) . On the other hand, the chalcone moieties of PC10 and PC11 formed π-π interactions with W286 and hydrogen bonds with the main chain of F295.

Chalcones are considered versatile scaffolds for many of the CNS-related agents, such as anti-depressants, anxiolytics, β-amyloid plaque imaging agents, adenosine receptor antagonists, and MAO-B and AChE inhibitors (Mathew et al. 2019b ). The three rotatable bonds available in the Michael acceptor between the two phenyl systems of chalcones provide different mode interactions in the inhibitor binding cavities of the enzymes, which are highly dependent on the natures and bulkinesses of groups bearing on the A and B chalcone rings (Matos et al. 2015) .

Recent studies have reported that the presence of electrondonating groups, such as methyl, methoxy, ethyl, dimethylamino, and ethyl acetohydroxamate, at the para position of the phenyl B ring of chalcones confers greater MAO-B inhibition than MAO-A inhibition. Lipophilic halogen atoms (fluorine, chlorine, and bromine) at the same position also resulted in outstanding MAO-B inhibition (Morales-Camilo et al. 2015; Reeta et al. 2019; Shalaby et al. 2019 ). In addition, the presence of an aliphatic or methyl-containing amino group or a nitrogen-derived pharmacophore in chalcones is required for AChE inhibition (Liu et al. 2016; Xiao et al. 2017; Bai et al. 2019) . In this respect, the present Fig. 3 Representations of the boiled-egg graphs (a and b) and bioavailability radar plots (c and d) for PC10 and PC11 produced using the SwissADME web-tool (Sasidharan et al. 2021 ).

In the present study, the unsubstituted piperazine-based chalcone (PC1) exhibited moderate MAO-B inhibition with an IC 50 value of 7.62 μM but high residual activities for MAO-A, AChE, BChE, and BACE-1 (96.6%, 72.9%, 96.0%, and 90.6%, respectively) at 10 μM. The introductions of small groups on the B ring of the phenyl system slightly impacted activity ratio toward multi-targets, which emphasizes the importance of substituents on the B ring. Some interesting structure-activity relationships (SARs) were derived, as depicted in Fig. 6 .

The SAR studies revealed that all piperazine-substituted chalcones inhibited MAO-B substantially or moderately better than MAO-A. The presence of electron-withdrawing groups like trifluoromethyl or fluorine provided good MAO-B inhibition and the presence of a methyl group (electron-donating) on the para position of the phenyl B ring provided optimal activity as exemplified by PC4, which had IC 50 values for MAO-B and AChE of 2.72 and 8.77 μM, respectively, and inhibited BACE-1 by 44.5% at 10 μM. Whereas the introduction of electron-donating groups like methyl (PC4), hydroxyl (PC2), or methoxy (PC3) groups resulted in moderate AChE inhibition (residual activities of 43.4%, 56.8%, and 58.8%, respectively, at 10 μM). Moreover, these electron-donating Regarding the effects of halogen substitution at phenyl ring on MAO-B inhibition, fluorine (PC10) had a greater effect than chlorine (PC8) or bromine (PC9). The high electronegativity of fluorine substituted phenyl in various molecular frameworks has been recently reported to increase hydrophobic interactions with Tyr398 and Tyr435 markedly in the active site of MAO-B .

MAO-B, AChE, and BACE-1 are important enzyme targets and can produce neurotoxic free radical by-products, degrade acetylcholine, and generate amyloid β (Aβ), and thus, the development of highly selective ligands that target these enzymes is of considerable interest to those involved in the development of drugs for AD (Moussa-Pacha et al. 2019; Benny and Thomas 2019). Recently, many researchers have used ligand or structure-based drug strategies to design dual-acting MAO-B/AChE inhibitors (Mathew 2020) . However, this is the first study to focus on the inhibitory profiles of piperazine containing chalcone-based compounds on MAO-A, MAO-B, AChE, BChE, and BACE-1. Our findings show that the lead molecules PC4, PC10, and PC11 selectively inhibit MAO-B at the submicromolar level and moderately inhibit AChE and BACE-1.

Reversible MAO-B inhibitors have shorter action durations than irreversible inhibitors because they dissociate from targets (Tipton 2018) . Many new reversible MAO-B inhibitors have been developed using various structural scaffolds, such as chromones, coumarins, chalcones, phenyloxazolidinones, and pyrazolines (Carradori and Silvestri 2015; Mathew et al. 2017; Mathew 2020) . Our reversibility studies on PC10 or PC11 inhibition of MAO-B indicate that the reversible natures of their interactions cause minimal target disruption and provide improved ADME profiles.

Computational results of interactions between PC4, PC10, or PC11 and MAO-A, MAO-B, or AChE targets provided satisfactory explanations of experimental data and agreed well with experimental IC 50 values. Furthermore, they showed that π-π interaction with Y326 of MAO-B (a selective residue), which is changed to I335 in MAO-A (Mangiatordi et al. 2017) , is a prerequisite for interaction in its binding pocket, as previously reported ).

We report the results of an investigation of the neuro-related, multi-enzyme targeting profiles of piperazine-bearing α,β-unsaturated ketones. The abilities of MAOs and ChEs inhibitions by the compounds were found to depend on the natures of substituents at the para position of the B phenyl ring of the chalcone framework. All eleven compounds inhibited MAO-B more than MAO-A, and compounds PC4, PC10, and PC11 potentially inhibited MAO-B with IC 50 values of 2.72, 0.65, and 0.71 μM, respectively, and moderately inhibited AChE with IC 50 values of 8.77, 28.0, and 26.3 μM, respectively. Furthermore, these experimental results were also supported by molecular docking studies. In addition, PC4, PC10, and PC11 moderately inhibited BACE-1 with IC 50 values of 15.5, 14.9, and 15.3 μM, respectively, which further supports their potential use for the development of novel drugs against various neurological disorders.

Rhamnocitrin isolated from Prunus padus var. seoulensis: a potent and selective reversible inhibitor of human monoamine oxidase A

Selective inhibition of monoamine oxidase A by hispidol

Development of chalcone-Oalkylamine derivatives as multifunctional agents against Alzheimer's disease

Integrated Modeling Program, Applied Chemical Theory (IMPACT)

Neurodegenerative diseases and oxidative stress

Essential oil as treatment for Alzheimer's disease: current and future perspectives

Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs

Piperazine derivatives with central pharmacological activity used as therapeutic tools

New frontiers in selective human MAO-B inhibitors

Design, synthesis, and biological evaluation of pyridazinones containing the (2-Fluorophenyl) Piperazine Moiety as Selective MAO-B Inhibitors

Structures of human acetylcholinesterase in complex with pharmacologically important ligands

Chalcones: a valid scaffold for monoamine oxidases inhibitors

SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules

A new and rapid colorimetric determination of acetylcholinesterase activity

Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy

The emergence of designed multiple ligands for neurodegenerative disorders

The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities

Chalcones: unearthing their therapeutic possibility as monoamine oxidase B inhibitors

Newly synthesized fluorinated cinnamylpiperazines possessing low in vitro MAO-B binding

Novel 1-(2-pyrimidin-2-yl)piperazine derivatives as selective monoamine oxidase (MAO)-A inhibitors

/ benzhydrylpiperazine derivatives as potential MAO inhibitors

Potent inhibition of acetylcholinesterase by sargachromanol I from Sargassum siliquastrum and by selected natural compounds

Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases

Design, synthesis and preliminary structure-activity relationship investigation of nitrogen-containing chalcone derivatives as acetylcholinesterase and butyrylcholinesterase inhibitors: a further study based on Flavokawain B Mannich base derivatives

Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments

A rational approach to elucidate human monoamine oxidase molecular selectivity

Privileged pharmacophore of FDA approved drugs in combination with chalcone framework: a new hope for Alzheimer's treatment

Exploration of chlorinated thienyl chalcones: a new class of monoamine oxidase-B inhibitors

Structural exploration of synthetic chromones as selective MAO-B inhibitors: a mini review

Selected aryl thiosemicarbazones as a new class of multi-targeted monoamine oxidase inhibitors

Potent and highly selective dual-targeting monoamine oxidase-B inhibitors: fluorinated chalcones of morpholine versus imidazole

Perspective design of chalcones for the management of CNS disorders: a minireview

New aspects of monoamine oxidase B inhibitors: the key role of halogens to open the golden door

Potential pharmacological uses of chalcones: a patent review

Design, synthesis, biological evaluation, and molecular modeling of coumarinpiperazine derivatives as acetylcholinesterase inhibitors

Synthesis, biological evaluation, and molecular simulation of chalcones and aurones as selective MAO-B inhibitors

BACE1 inhibitors: current status and future directions in treating Alzheimer's disease

Novel class of chalcone oxime ethers as potent monoamine oxidase-B and acetylcholinesterase inhibitors

Uysal M (2020) Synthesis, molecular modelling and biological activity of some pyridazinone derivatives as selective human monoamine oxidase-B inhibitors

Synthesis and evaluation of a set of para-substituted 4-phenylpiperidines and 4-phenylpiperazines as monoamine oxidase (MAO) inhibitors

Piperazine derivatives for therapeutic use: a patent review (2010-present)

Ethyl acetohydroxamate incorporated chalcones: unveiling a novel class of chalcones for multitarget monoamine oxidase-B inhibitors against Alzheimer's disease

Selected furanochalcones as inhibitors of monoamine oxidase

Design, synthesis, in vitro and in silico studies of new thiazolylhydrazinepiperazine derivatives as selective MAO-A inhibitors

Thiazole-substituted benzoylpiperazine derivatives as acetylcholinesterase inhibitors

Identification of indole-based chalcones: discovery of a potent, selective, and reversible class of MAO-B inhibitors

Imidazole bearing chalcones as a new class of monoamine oxidase inhibitors

Morpholine based chalcones as dual acting monoamine oxidase-B and acetylcholinesterase inhibitors. Synthesis and biochemical investigations

SAR and molecular mechanism studies of monoamine oxidase inhibition by selected chalcone analogs

Structure of human monoamine oxidase A at 2.2-A resolution: the control of opening the entry for substrates/inhibitors

90 years of monoamine oxidase: some progress and some confusion

Synthesis and antimicrobial evaluation of new chalcones containing piperazine or 2,5-dichlorothiophene moiety

Novel approaches for the treatment of Alzheimer's and Parkinson's disease

Design, synthesis and biological evaluation of 4'-aminochalcone-rivastigmine hybrids as multifunctional agents for the treatment of Alzheimer's disease

Multi-target design strategies for the improved treatment of Alzheimer's disease

Chalcone: a privileged structure in medicinal chemistry

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations

Acknowledgements This work was supported by Taif University